NuVision is managed by an expert team of directors encompassing essential skills of business development, clinical ophthalmic surgery, medical affairs, GMP manufacturing and research and development. Together we create a unique dynamic that will enable the company to grow and evolve to redefine sight saving biotherapies.
Dr Mark Treherne
Mark Treherne joined the NuVision team in 2018 as Chairman of the company. Mark has a PhD in Pharmacology from Cambridge University along with over 25 years of industrial R&D experience in the discovery and development of novel treatments for diseases with unmet medical need. Mark is also currently Chairman of Talisman Therapeutics and Chief Executive of Avilex Pharma.
Prior to this, Mark has carried out research work with Pfizer and in 1997 set up Cambridge Drug Discovery (CDD) as Chief Executive which was sold to BioFocus in 2001.
Mark was formerly Chairman of ERBI for 3 years, which represents the biotechnology companies in the East of England (now One Nucleus). He was also Chief Executive of the Life Sciences Organisation of UK Trade & Investment until 2016. Mark is an author of over 70 articles published in the scientific and trade press.
Andrew Hopkinson, PhD, is the Chief Executive Officer, founder and visionary of NuVision. Andrew has 15 years’ translational research expertise in ophthalmic regenerative medicine as the Principal Research Fellow at Nottingham Centre For Eye research, which is part of Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham.
During his time at the University he and his multidisciplinary research team have been engaged in developing innovative technologies to repair and regenerate the injured ocular surface for visual rehabilitation. His research pioneered the development of Tereo processing and Omnigen. He continues to drive ground breaking research discoveries from the bench to pre-clinical and clinical realisation, to create an exciting future portfolio of innovative Biotherapies for NuVision.
During his academic career, Dr Hopkinson has published over 50 scientific papers in leading journals in the fields of ophthalmology and tissue engineering, and has filed 4 patents.
Dr Andrew Hopkinson
Mr Peter Dines
As a highly successful entrepreneur and investor, Peter heads up Life Science Investments at Mercia Fund Management.
He has over 20 years’ experience in the healthcare sector, where during this period, Peter founded Surgi C Group which he grew and sold to a private equity backed company. Other key healthcare positions held include Cisiv, Diagnostic World and Spring Active.
Roger Teasdale joined the Board as an Independent Non-Executive Director in 2018. Roger enjoyed a successful 25 year career at Smith & Nephew, the FTSE 100 Medical device business focused on the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of $4.8bn and operations in 120 countries. For his last 5 years at Smith & Nephew, Roger was President of the Global Advanced Wound Management business with sales of $1.4bn and 4000 people in 80 countries. Roger gained a proven international track record in driving revenue and profit growth in the medical device industry. His most recent role is Group Managing Director at Premier Technical Services Group, a listed niche specialist service provider. Roger is a qualified Chartered Accountant and holds a BA in Accounting and Management Control.
Independent Non-Executive Director
Sales & Marketing Director
Jonathan Hamill-Keays joined the NuVision in 2018 as our Sales and Marketing Director. Jonathan has over 30 years experience in clinical research, Sales and Marketing and Business Development. Previous positions include working in Operations at Smith Klein & French, clinical data management at Glaxo Laboratories and Clinical Research Manager at Serono Laboratories prior to completing an MBA at Bradford University. Jonathan joins us from Chiesi Ltd, where he established and grew their Specialist Medicines Division in the UK including the launch of products in Neonatal Intensive Care, Cystic Fibrosis and Transplantation. Jonathan’s extensive knowledge and expertise in driving sales together with management and leadership skills will be hugely beneficial to NuVision as the company expands.
Dr Adriana Oikonomou is our HTA Designated Individual. She ensures the quality of our products are manufactured to a high standard and deals with the regulatory aspects of the company.
Dr Adriana Oikonomou
HTA Designated Individual
María J. Mendoza is the Process Development Officer at NuVision. Her experience includes molecular, cell biology and immunology research. Graduated from the University of Nottingham with a MSc. in Stem Cell Technology, she has knowledge of regenerative therapies and translational technologies. As an intern in NuVision, Maria has been involved in the translation and implementation of OmnigenTM manufacture into clinical standards. She oversees OmnigenTM manufacture, process development and translation of new research technologies into clinical standards following the HTA requirements.
Dr Emily Britchford is the Research and Development Officer at NuVision. She has several years’ experience in both academic and applied scientific research. Emily has recently graduated with a PhD in Tissue Engineering at the University of Nottingham as part of the EPSRC doctoral training program in regenerative medicine.
Emily has a dual role also working as a post-doctoral research associate in Academic Ophthalmology at the University of Nottingham. Her research interests focus on the development of Omnigen application for acute ocular surface trauma.
Dr Emily Britchford
Research and Development Officer
International Business Development Executive
Rachel Hampson joined the NuVision team as part of a University of Nottingham internship in September 2016. Rachel has worked on the processing and manufacturing of Omnigen in the laboratory and engages in the regulatory functions of the business with regards to distribution of Omnigen across the globe. Rachel’s primary role is to establish partnerships and distribution agreements in new international markets in order to extend the reach of Omnigen globally.
Rachel holds a BSc (Hons) in Biology and an MSc in Clinical Microbiology, both from the University of Nottingham.
Rebecca has a degree in Bioveterinary Science from The University of Liverpool.
She has gained experience in sales, marketing and administration through
She will be product specialist for veterinary customers as well as being
involved in manufacturing Omnigen and maintaining the Tissue Processing Facility.
Veterinary Liaison Officer
Adrian Del Arenal Martin
Adrian Del Arenal Martin has joined the team as a Intern Manufacturing Technician. He is a Biotechnology Engineer with experience in recombinant protein bioprocessing. He graduated from the University of Nottingham with a MSc. in Biopharmaceutics and Business and has gained start-up business knowledge as a intern SME consultant at BioCity.
Adrian will be working on clinical sales as well as manufacturing our products.
Our sales team was established in 2018 in order to ensure greater customer services to those already using our product and to also raise awareness throughout the UK, in both the NHS and private hospitals.
Sandra Johnson, Lynn Paine & Julie Munroe
Territory Development Managers
Interested in purchasing Omnigen?
Register your interest
Have a question about our products or pipelines?
Speak to our team of experts